MedNews: FDA Grants Full Approval for Pfizer's and Genmab's TIVDAK to Treat Recurrent or Metastatic Cervical Cancer
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent...